Systematic Evaluation Of Piperazine Ferulate Combined With Irbesartan In The Treatment Of Diabetic Kidney Disease

Objective:To systematically evaluate the efficacy and safety of piperazine ferulate(PF)combined with Irbesartan in the treatment of diabetic kidney disease(DKD).Methods:According to the formulated search strategy,use computer to search Chinese and English database,Clinical Trial Registration Platform,grey literature and citation tracking,manual search related literature.Clinical randomized controlled trials of PF and irbesartan in the treatment of DKD were comprehensively collected,and the final studies were selected according to the exclusion criteria.The two authors independently extracted data according to a unified data sheet and evaluated the quality of the included studies.Finally,Revman5.3 statistical software was used to perform statistical analysis on the relevant indicators of the included research.Results:Eleven clinical randomized controlled trials were finally included,all of which were implemented in China.A total of 1,290 patients,including 644 in the intervention group(PF and irbesartan)and 643 in the control group(irbesartan alone).The results suggest:(1)compared with the control group,the intervention group can more effectively reduce urinary protein excretion rate,24-hour urine protein,fasting blood glucose,2-hour postprandial blood glucose and serum creatinine,P?0.05,the difference is statistically significant;(2)Compared with the control group,the intervention group had no significant difference in the effects on systolic blood pressure,blood urea nitrogen,P>0.05,and the difference was not statistically significant;(3)Compared with the control group,the total effective rate of the intervention group is increased without increasing the incidence of adverse reactions,and the treatment safety is good.Conclusion:Compared with irbesartan alone group,PF combined with irbesartan group can more effectively improve the prognostic indicators of DKD patients,such as urinary protein excretion rate,24-hour urine protein,fasting blood glucose and 2-hour postprandial blood glucose,but due to the methodological quality of the included literature and research is not high,and higher quality studies are needed to further confirm its efficacy and safety.